X

Trial Profile

A phase Ib/II study of BL-8040 in combination with Atezolizumab in patients with non-small cell cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Motixafortide (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors Genentech

Most Recent Events

21 Nov 2017 According to a BioLineRx media release, the company expects to initiate this trial by early 2018
06 Jun 2017 New trial record
01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial and the company expects to initiate this trial in the second half of 2017 after receipt of regulatory approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com